| Literature DB >> 23632427 |
Monika Pobiega1, Jadwiga Wojkowska-Mach, Agnieszka Chmielarczyk, Dorota Romaniszyn, Paweł Adamski, Piotr B Heczko, Barbara Gryglewska, Tomasz Grodzicki.
Abstract
BACKGROUND: The aim of this study was to assess the prevalence of multidrug-resistant Escherichia coli and extended-spectrum â-lactamases (ESBL) pathogens isolated from asymptomatic bacteriuria and urinary tract infections (UTIs), and the relationship between the phylogeny, antimicrobial resistance, and virulence among isolates in residents of 3 long-term care facilities (LTCF) in Krakow, Poland.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23632427 PMCID: PMC3659068 DOI: 10.12659/MSM.883898
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Characteristics of studied population at baseline.
| Type of care/Characteristics of studied population | Home care | Residential homes | Nursing homes | p-value | |||
|---|---|---|---|---|---|---|---|
| Male residents | 6 | 25.0 | 36 | 41.9 | 35 | 32.7 | – |
| Female residents | 18 | 75.0 | 50 | 58.1 | 72 | 67.3 | |
| Residents recently hospitalized | 6 | 25.0 | 20 | 23.3 | 8 | 7.5 | <0.001 |
| Urinary incontinence: diapers | 6 | 25.0 | 23 | 26.7 | 39 | 36.4 | <0.001 |
| Permanent catheterization into the bladder | 1 | 4.2 | 0 | 0.0 | 39 | 36.4 | |
| Stool incontinence | 4 | 16.7 | 6 | 7.0 | 67 | 62.6 | <0.001 |
| Dysphagia | 0 | 0.0 | 4 | 4.7 | 26 | 24.3 | <0.001 |
| Stomach probe | 0 | 0.0 | 0 | 0.0 | 26 | 24.3 | <0.001 |
| Tracheostomy tube | 0 | 0.0 | 1 | 1.2 | 4 | 3.7 | – |
Figure 1Plot showing % of strains resistant to tested antibiotics according to ESBL activity. (AMP – ampicillin, TZP – piperacillin/tazobactam, CAZ – ceftazidime, CTX – cefotaxime, FEP – cefepime, CXM – cefuroxime, ATM – aztreonam, IPM – imipenem, CN – gentamicin, CIP – ciprofloxacin, SXT – trimethoprim/sulfamethoxazole, F – nitrofurantoin).
Risk factors for ESBL presence in Long-Term Care Facilities (LTCFs).
| Type of care/Characteristics of studied population | ESBL | Non-ESBL residents [no/%] | p-value | ||
|---|---|---|---|---|---|
| Male | 3 | 20.0 | 74 | 34.1 | – |
| Female | 10 | 80.0 | 130 | 65.9 | |
| Type of care | 15 | 100.0 | 202 | 93.1 | – |
| RH | 4 | 26.7 | 82 | 37.8 | – |
| NH | 10 | 66.7 | 97 | 44.7 | |
| Infection treated in a hospital | 3 | 20.0 | 17 | 7.8 | – |
| Death with infection | 5 | 33.3 | 11 | 5.1 | <0.001 |
| Hospitalisation before enrollment | 5 | 33.3 | 28 | 12.9 | 0.045 |
| Urinary incontinence: pampers | 10 | 66.7 | 58 | 26.7 | <0.001 |
| Urinary incontinence: catherization | 5 | 33.3 | 35 | 16.1 | |
| Stool incontinence | 11 | 73.3 | 66 | 30.4 | <0.001 |
| Dysphagia | 5 | 33.3 | 25 | 11.5 | 0.023 |
| Stomach probe | 5 | 33.3 | 21 | 9.7 | 0.008 |
| Tracheotomy tube | 2 | 13.3 | 3 | 1.4 | 0.003 |
| Barthel Index | |||||
| 0 | 6 | 40.0 | 27 | 12.4 | |
| 1–15 | 3 | 20.0 | 33 | 15.2 | |
| 16–50 | 3 | 20.0 | 54 | 24.9 | 0.001 |
| 51–75 | 3 | 20.0 | 9 | 4.1 | |
| 76–100 | 0 | 0.0 | 76 | 35.0 | |
| Katz Index | |||||
| 0–1 | 11 | 73.3 | 80 | 36.9 | |
| 2–4 | 3 | 20.0 | 30 | 13.8 | 0.015 |
| 5–6 | 1 | 6.7 | 87 | 40.1 | |
| Mobility | |||||
| Independent, with no restrictions – 1 | 0 | 0.0 | 65 | 30.0 | |
| Independent, with no restrictions, repeated falls – 2 | 2 | 13.3 | 8 | 3.7 | |
| Limitation in mobility – 3 | 3 | 20.0 | 74 | 34.1 | <0.001 |
| Lying, self-changing body position – 4 | 3 | 20.0 | 18 | 8.3 | |
| Lying, dependent – 5 | 7 | 46.7 | 35 | 16.1 | |
ESBL – extended-spectrum β-lactamase;
RH – residential home;
NH – nursing home.
Escherichia coli isolates used and described during this study – characteristics.
| Isolate | β-lactamase(s) | Resistance profile | ECOR | Virulence factors |
|---|---|---|---|---|
| 384 | CTX-M-15, TEM-1 | CAZ ATM CTX FEP AMC AMP CXM SXT CN CIP | B2 | |
| 369 | CTX-M-15 | CAZ ATM CTX FEP AMC AMP CXM SXT CIP | B2 | |
| 359 | CTX-M-15, TEM-1 | CAZ ATM CTX FEP AMP CXM CN CIP TZP | B2 | |
| 79 | TEM-1 | CAZ ATM CTX AMP CXM CN CIP | A | |
| 61 | TEM-1 | ATM CTX AMP CXM SXT CIP F | B2 | |
| 71 | TEM-1 | ATM CTX AMC AMP CXM SXT | D | |
| 82 | CTX AMP CXM SXT CIP F | B2 | ||
| 375-1 | CTX AMP CXM SXT CIP | B2 | ||
| 81 | CTX AMP CXM SXT CIP | B2 | ||
| 208 | CTX AMP CXM SXT CIP | B2 | ||
| 363 | AMP SXT CN CIP | D | ||
| 76 | CAZ AMP SXT | A | ||
| 77 | AMP SXT CN | D | ||
| 355 | AMP SXT CIP | B2 | ||
| 362 | AMP SXT CIP | B2 | ||
| 386-2 | AMP SXT CIP | A | ||
| 78 | AMP CIP | B2 | ||
| 213 | AMP SXT | B2 | ||
| 214 | AMP SXT | B2 | ||
| 205 | AMP SXT | D | ||
| 284 | SXT CIP | D | ||
| 372 | AMP SXT | D | ||
| 375-2 | SXT CIP | B2 | ||
| 376 | AMP CIP | B2 | ||
| 381 | AMP SXT | D | ||
| 403 | ATM AMP | B2 | ||
| 417 | AMP CIP | B2 | ||
| 660 | AMP CIP | ? | ||
| 285-2 | AMP | B2 | ||
| 290 | AMP | B2 | ||
| 298 | AMP | B2 | ||
| 74 | SXT | A | ||
| 75 | CIP | B2 | ||
| 63 | AMP | A | ||
| 60 | AMP | A | ||
| 270 | F | B2 | ||
| 271 | CIP | AA | ||
| 278 | AMP | B2 | ||
| 374 | AMP | B2 | ||
| 405 | AMP | B2 | ||
| 406 | AMP | B1 | ||
| 437 | CAZ | D | ||
| 667 | AMP – LACK OF DATA | ? | ||
| 423 | B2 | |||
| 430 | A | |||
| 441-2 | B2 | |||
| 633 | ||||
| 62 | D | |||
| 70 | A | |||
| 73 | A | |||
| 88 | B2 | |||
| 281 | B2 | |||
| 282 | A | |||
| 287-2 | A | |||
| 292 | B2 | |||
| 297 | A | |||
| 352 | B2 | |||
| 353 | B1 | |||
| 357 | D |
Antimicrobials: AMP – ampicillin; TZP – piperacillin/tazobactam; CAZ – ceftazidime; CTX – cefotaxime; FEP – cefepime; CXM – cefuroxime; ATM – aztreonam; IPM – imipenem; CN – gentamicin; CIP – ciprofloxacin; SXT – trimethoprim/sulfamethoxazole; F – nitrofurantoin.
The strains were classified according to the ECOR system by the use of the rapid phylogenetic grouping technique described by Clermont et al. (Clermont 2000). This method is based on a multiplex PCR involving the amplification of two genes (chuA and yjaA) and of an anonymous fragment of DNA from E. coli (TspE4C2). the results are interpreting as follows: chuA and yjaA positive: group B2; chuA positive and yjaA negative: group D; chuA negative and TspE4C2 positive: group B1; chuA negative and TspE4C2 negative – group A.
It was impossible to grow the strain after freezing.